{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_relationships_relatedSubstance_refPname in Related Substance Name (approximate match)
Status:
US Approved Rx
(2002)
Source:
BLA125057
(2002)
Source URL:
First approved in 2002
Source:
BLA125057
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:vixarelimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01280903: Not Applicable Interventional Completed Osteoarthritis, Knee
(2012)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT03534063: Not Applicable Interventional Completed Pain, Postoperative
(2018)
Source URL:
Class:
PROTEIN